14.4 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing
Key Takeaways
- Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) represent life-threatening severe cutaneous adverse reactions (SCARs) driven by cytotoxic CD8+ T-cell and NK-cell release of granulysin, perforin/granzyme B, and Fas-FasL, inducing massive pan-epidermal keratinocyte apoptosis and pan-mucosal sloughing.
- The disease continuum is classified strictly by the extent of Body Surface Area (BSA) exhibiting epidermal detachment: SJS (<10% TBSA with ≥2 mucosal sites), SJS/TEN Overlap (10% to 30% TBSA), and TEN / Lyell's Syndrome (>30% TBSA detachment).
- The SCORTEN prognostic scoring system evaluates 7 independent clinical and laboratory parameters calculated within the first 24 hours of admission (Age ≥40, HR ≥120, Malignancy, BSA detachment ≥10%, BUN >28 mg/dL, Glucose >252 mg/dL, Bicarbonate <20 mEq/L); a SCORTEN ≥5 predicts ~90% in-hospital mortality.
- Wound care in SJS/TEN strictly CONTRAINDICATES surgical debridement or tangential excision because the underlying dermis is vital and intact; nursing management mandates leaving detached epidermis in situ as a biological dressing roof, gentle non-shear wound cleansing, and applying non-adherent silicone or biosynthetic barriers.
- Immediate cessation of all suspect/culprit medications and early transfer to an ABA-verified burn center cuts mortality in half, while intensive emergency ophthalmologic care (preservative-free lubrication, daily symblepharon lysis, and amniotic membrane grafting) is mandatory to prevent permanent blindness.
14.3 Severe Cutaneous Adverse Reactions: Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), SCORTEN, and Specialized Burn Unit Nursing
Core Knowledge: Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN, or Lyell's Syndrome) are acute, life-threatening severe cutaneous adverse reactions (SCARs) characterized by extensive keratinocyte apoptosis, widespread epidermal necrolysis, and severe multi-mucosal sloughing. Although not caused by thermal energy, SJS and TEN produce systemic pathophysiological sequelae identical to major partial-thickness thermal burns—including massive evaporative fluid loss, electrolyte derangements, catastrophic barrier failure, hypermetabolism, and sepsis. Specialized burn center admission, conservative non-surgical wound preservation, meticulous multi-mucosal care (especially ocular preservation), and prompt drug discontinuation are essential to patient survival.
1. Pathophysiology and Immunobiology of SJS / TEN
SJS and TEN represent a disease continuum triggered predominantly by a delayed, cell-mediated (Type IVc) hypersensitivity reaction to specific medications.
IMMUNOPATHOLOGICAL CASCADE IN SJS / TEN
┌────────────────────────────────────────────────────────────────────────┐
│ 1. DRUG-MHC CLASS I PRESENTATION & T-CELL ACTIVATION │
│ • Culprit drug metabolite binds to Human Leukocyte Antigen (HLA-I). │
│ • Clonally expanded cytotoxic CD8+ T-lymphocytes & Natural Killer cells│
│ infiltrate the dermo-epidermal junction. │
├────────────────────────────────────────────────────────────────────────┤
│ 2. MASSIVE RELEASE OF CYTOTOXIC MEDIATORS │
│ • GRANULYSIN (Primary Mediator): 15-kDa cytolytic pore-forming protein │
│ secreted in blister fluid; directly triggers widespread keratinocyte │
│ necroptosis and apoptosis. Levels correlate with disease severity. │
│ • Perforin & Granzyme B: Cleave caspase cascades within target cells. │
│ • Soluble Fas Ligand (sFasL): Binds Fas receptor (CD95) on basal │
│ keratinocytes, initiating death-receptor-mediated apoptosis. │
├────────────────────────────────────────────────────────────────────────┤
│ 3. HISTOPATHOLOGICAL SEPARATION: Full-thickness epidermal necrosis │
│ with subepidermal split at the dermo-epidermal basement membrane; │
│ the underlying DERMIS REMAINS VIABLE AND INTACT. │
└────────────────────────────────────────────────────────────────────────┘
Differentiation from Staphylococcal Scalded Skin Syndrome (SSSS):
- In SJS/TEN, apoptosis occurs across the entire full-thickness epidermis, causing separation at the dermo-epidermal junction (subepidermal split) with mucosal involvement in $>90%$ of cases.
- In SSSS, Staphylococcus aureus exfoliative toxins A and B cleave desmoglein-1, producing a superficial intraepidermal split at the stratum granulosum; mucous membranes are spared, and mortality is low ($<5%$ in children).
2. High-Risk Causative Medications and Genetic Susceptibility
Over 85% of TEN cases and 70% of SJS cases are drug-induced. Symptoms typically manifest 1 to 3 weeks (7 to 21 days) following initial drug exposure (or within hours upon re-exposure).
HIGH-RISK CULPRIT MEDICATIONS MATRIX
┌─────────────────────────┬─────────────────────────┬─────────────────────────┐
│ Medication Class │ Specific Common Agents │ High-Risk Allele / Notes│
├─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Anti-Gout / Xanthine │ Allopurinol │ HLA-B*58:01 │
│ Oxidase Inhibitors │ │ (Highest global cause) │
├─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Aromatic Antiepileptics │ Carbamazepine, Phenytoin│ HLA-B*15:02 (Asian) │
│ │ Lamotrigine, Phenobarb. │ HLA-A*31:01 (European) │
├─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Sulfonamide Antibiotics │ Trimethoprim- │ Common in both adults │
│ │ sulfamethoxazole (Bactrim)│ and pediatric cohorts │
├─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ NSAIDs (Oxicam Class) │ Piroxicam, Meloxicam │ Highest risk among │
│ │ │ all NSAID classes │
├─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Antiretrovirals (NNRTI) │ Nevirapine │ High incidence in HIV+ │
├─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Other Antibiotics │ Cephalosporins, Quinol- │ Broad-spectrum exposure │
│ │ ones, Aminopenicillins │ │
└─────────────────────────┴─────────────────────────┴─────────────────────────┘
3. Disease Classification Spectrum and Clinical Presentation
The disease spectrum is classified based on the percentage of total body surface area exhibiting actual or impending epidermal detachment:
SJS / TEN SPECTRUM CLASSIFICATION
┌────────────────────────────────────────────────────────────────────────┐
│ STEVENS-JOHNSON SYNDROME (SJS) │
│ • Epidermal Detachment: < 10% TBSA │
│ • Multi-mucosal involvement (≥ 2 anatomical sites) in > 90% of cases │
│ • Expected Mortality: 1% – 5% │
├────────────────────────────────────────────────────────────────────────┤
│ SJS / TEN OVERLAP SYNDROME │
│ • Epidermal Detachment: 10% to 30% TBSA │
│ • Widespread atypical targetoid macules with confluent purpuric patches│
│ • Expected Mortality: 10% – 15% │
├────────────────────────────────────────────────────────────────────────┤
│ TOXIC EPIDERMAL NECROLYSIS (TEN / Lyell's Syndrome) │
│ • Epidermal Detachment: > 30% TBSA (frequently > 50%–70% TBSA) │
│ • Sheet-like epidermal sloughing, severe pan-mucosal ulceration │
│ • Expected Mortality: 25% – 50% (up to 90% with high SCORTEN) │
└────────────────────────────────────────────────────────────────────────┘
Clinical Phases and Hallmark Physical Signs:
- Prodromal Phase (1 to 3 Days Prior to Rash): High-grade fever ($>38.5^\circ\text{C}$), malaise, severe sore throat, stinging/photophobia of the eyes, arthralgias, and dysphagia.
- Exanthematous Phase: Symmetrical eruption of tender, dusky erythematous macules or flat, atypical 'targetoid' lesions (2 concentric rings, unlike typical 3-ring erythema multiforme) starting on the face and trunk before spreading to extremities.
- Necrotic / Bullous Phase: Lesions coalesce into large, flaccid bullae containing clear or serosanguinous fluid.
- Hallmark Physical Examination Signs:
- Positive Nikolsky Sign: Gentle lateral mechanical sliding pressure applied with a finger on normal-appearing perilesional or erythematous skin produces dislodgement and peeling of the epidermis from the dermis.
- Positive Asboe-Hansen Sign (Bullous Spread Sign): Vertical pressure applied to the center of an intact flaccid blister forces fluid to dissect laterally under adjacent uninjured epidermis.
- Multi-Mucosal Involvement ($\ge 2$ Sites in $>90%$):
- Ocular: Severe conjunctival injection, chemosis, pseudomembrane formation, corneal erosions, and symblepharon.
- Oral: Hemorrhagic crusting of vermilion borders, painful denudation of buccal mucosa, palate, and pharynx.
- Urogenital: Erosive vaginitis, vulvar ulceration, urethritis, labial or foreskin synechiae.
- Respiratory / GI: Tracheobronchial epithelial sloughing (requiring mechanical ventilation), severe esophageal erosions.
4. SCORTEN Prognostic Scoring System
SCORTEN is the internationally validated prognostic score developed by Bastuji-Garin et al. to predict in-hospital mortality in SJS and TEN. It comprises 7 independent clinical and laboratory variables, each scored as 1 point if present. SCORTEN must be calculated within the first 24 hours of admission, and ideally recalculated on Day 3 to capture disease progression.
THE 7 SCORTEN VARIABLES MATRIX
┌───┬──────────────────────────────────┬─────────────────────────────────┐
│ # │ SCORTEN Parameter │ Criterion Threshold (1 Pt Each) │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 1 │ Age │ ≥ 40 years │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 2 │ Heart Rate │ ≥ 120 beats/min │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 3 │ Associated Malignancy │ Present (Cancer / Hematologic) │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 4 │ Epidermal Detachment on Day 1 │ ≥ 10% TBSA │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 5 │ Serum Urea / BUN │ > 28 mg/dL (> 10 mmol/L) │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 6 │ Serum Glucose │ > 252 mg/dL (> 14 mmol/L) │
├───┼──────────────────────────────────┼─────────────────────────────────┤
│ 7 │ Serum Bicarbonate (HCO3-) │ < 20 mEq/L (< 20 mmol/L) │
└───┴──────────────────────────────────┴─────────────────────────────────┘
SCORTEN MORTALITY CORRELATION BENCHMARK
┌─────────────────────┬───────────────────┬──────────────────────────────┐
│ Total SCORTEN Score │ Predicted Mortality│ Clinical Acuity │
├─────────────────────┼───────────────────┼──────────────────────────────┤
│ Score 0 – 1 │ 3.2% │ Low Risk │
│ Score 2 │ 12.1% │ Moderate Risk │
│ Score 3 │ 35.3% │ High Risk │
│ Score 4 │ 58.3% │ Very High Risk │
│ Score ≥ 5 │ 90.0% │ Critical / Extreme Mortality │
└─────────────────────┴───────────────────┴──────────────────────────────┘
5. Specialized Burn Unit Nursing & Medical Management
Admission to an American Burn Association (ABA)-verified Burn Intensive Care Unit significantly reduces mortality in TEN compared to treatment on general medical or dermatology wards.
TEN BURN UNIT NURSING & MEDICAL PROTOCOL
┌────────────────────────────────────────────────────────────────────────┐
│ STEP 1: IMMEDIATE ELIMINATION OF THE CULPRIT DRUG │
│ • Instantly discontinue all non-essential and suspect medications. │
│ • Drugs with shorter elimination half-lives improve survival when │
│ withdrawn early. Never re-challenge with cross-reactive classes. │
├────────────────────────────────────────────────────────────────────────┤
│ STEP 2: CONSERVATIVE NON-SURGICAL WOUND CARE (STRICT NO-EXCISION) │
│ • SURGICAL EXCISION IS STRICTLY CONTRAINDICATED. The dermis is viable. │
│ • Biological Roof Preservation: Leave detached, non-viable epidermis │
│ in situ as a natural barrier to prevent fluid loss and infection. │
│ • Gentle Irrigation: Sterile warm saline or 0.05% chlorhexidine. │
│ • Non-Adherent Dressings: Apply soft silicone contact layers (Mepitel) │
│ or biosynthetic temporary membranes (Biobrane, Suprathel, Allograft).│
│ • AVOID Silver Sulfadiazine: Cross-reactive sulfa risk + leukopenia. │
├────────────────────────────────────────────────────────────────────────┤
│ STEP 3: EMERGENCY OPHTHALMOLOGICAL PRESERVATION │
│ • Ophthalmology consult within 2 to 4 hours of BICU arrival. │
│ • Preservative-Free Lubricants: Instill drops/ointments q 1–2 hours. │
│ • Mechanical Symblepharon Lysis: Daily sweeping of fornices with a │
│ sterile glass rod / muscle hook to prevent palpebral-bulbar adhesions│
│ • Cryopreserved Amniotic Membrane Transplantation (AMT): Grafted over │
│ palpebral conjunctiva & cornea within 48–72h to halt blinding fibrosis│
├────────────────────────────────────────────────────────────────────────┤
│ STEP 4: UROGENITAL & ORAL MUCOSAL HYGIENE │
│ • Oral: Viscous lidocaine, diphenhydramine, and chlorhexidine rinses. │
│ • Urogenital: Lubricating petrolatum gauze to denuded vulva/penis; │
│ soft vaginal molds/stents to prevent vaginal canal obliteration / │
│ stenosis; indwelling catheter during active urethral sloughing. │
├────────────────────────────────────────────────────────────────────────┤
│ STEP 5: SYSTEMIC IMMUNOMODULATORY THERAPIES │
│ • High-Dose IVIG (Intravenous Immunoglobulin, 2–3 g/kg total over 3–4d)│
│ -> Blocks Fas-FasL-mediated keratinocyte apoptosis. │
│ • Cyclosporine A (3–5 mg/kg/day IV/oral) -> Calcineurin inhibitor that │
│ blocks CD8+ T-cell and NK-cell activation and halts granulysin. │
│ • TNF-alpha Inhibitors (Etanercept 50 mg SC once) -> Rapid anti- │
│ inflammatory effect; promotes accelerated re-epithelialization. │
└────────────────────────────────────────────────────────────────────────┘
Critical Difference in Resuscitation Fluids:
Unlike thermal burns which destroy both epidermis and dermis and require massive crystalloid formulas ($3\text{--}4\text{ mL/kg/%TBSA}$), SJS/TEN fluid requirements are approximately two-thirds of thermal burn formulas (roughly $2.0\text{ mL/kg/% epidermal detachment}$) because the underlying dermal vascular plexus remains partially intact. Fluid must be carefully titrated to maintain adult urine output at 0.5 mL/kg/hr while avoiding fluid creep and pulmonary edema.
A 55-year-old female with a history of lymphoma is admitted to the burn ICU 10 days after starting carbamazepine. Physical examination reveals flaccid bullae with 25% TBSA epidermal detachment, positive Nikolsky sign, and extensive oral and ocular sloughing. Admission laboratory values show: HR 126 bpm, BUN 32 mg/dL, serum glucose 264 mg/dL, and serum bicarbonate 22 mEq/L. What is this patient's SCORTEN score, and what is her predicted in-hospital mortality?
Why is surgical tangential excision strictly contraindicated in the management of Toxic Epidermal Necrolysis (TEN), in direct contrast to thermal burn management?
A patient with 40% TBSA Toxic Epidermal Necrolysis (TEN) exhibits bilateral conjunctival hyperemia, severe photophobia, pseudomembrane formation, and denudation of the tarsal conjunctiva. Which specialized nursing and medical interventions are paramount within the first 48 hours to prevent symblepharon and permanent visual loss?